Quertle introduces data platform to enable deep dives into scientific literature

Data science

Quertle has introduced a data analytics and visualization platform designed to enable researchers to unearth relevant information from the thicket of journal articles, patents and other documents that make up the scientific record.

Henderson, NV-based Quertle has spent years working on making it easier to search the scientific record, in which time it has won the National Library of Medicine’s software development challenge. Now, Quertle has introduced a platform called BioAI to improve its search features, while also adding visualization capabilities.

“BioAI combines the latest advances in AI using neural networks with natural language recognition,” Quertle CEO Jeff Saffer said in a statement. “This will enhance drug discovery, accelerating a return on investment, and improve processes across the industry.”

Infographic Download

Reducing Time to Clinic for Your Biomedical Applications

Gelatin methacryloyl (GelMA)-based biomaterials have been widely used in various biomedical research applications due to their suitable biological properties and tunable physical characteristics. Especially over the past 5 years, GelMA-oriented research and patent applications have been growing exponentially, and many of these research concepts are now being translated towards the clinic. Suitable GelMA biomaterials are therefore indispensable to keep pace with the newest medical innovations.

Download to learn more about the benefits of GelMA in various biomedical applications and how X-Pure® GelMA can help you in your developments.

Saffer cofounded Quertle with long-term collaborator Vicki Burnett in 2009. Prior to setting up the company, Saffer and Burnett worked together at OmniViz and SciWit, both of which were involved in the development of software to analyze scientific data.

This interest in life science data analytics and visualization has now manifested in BioAI and the Qinsight product it underpins. Using Qinsight, researchers can sift through PubMed, patents, grant applications to the National Institutes of Health and other sources in search of information that can inform their programs and understanding of the competitive landscape.

None of this information is proprietary. What Quertle is selling is the ability to dig faster and deeper into the expanding repository of information that is available online to identify relevant information, and only relevant information.

To demonstrate why its platform is better than free alternatives, Quertle cites a handful of use cases, including one detailing what happens when a drug discovery team wants to find information on nitric oxide regulated pathways. As, according to Quertle, one-fifth of the scientific literature about nitric oxide refers to it only as NO, it can be hard to home in on relevant papers. Qinsight, in contrast, knows that in this context NO means nitric oxide and adjusts its search accordingly.

Suggested Articles

A few years ago, one of our Fierce editors met a Big Pharma R&D chief for the first time. “You’re the ones with the scary name,” he joked.

There's no evidence personal patient information leaked during the 11-week breach, but the same can't be said about Sangamo's own secrets.

Through a new online tracker, AllTrials names sponsors who fail to report clinical trial results on time per the FDAAA Final Rule.